Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 10/20 | 0.42 |
| ▸ | FEN1 | P39748 | 10/20 | 0.42 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17670765 | 0.87 | BTK (0.41) | ALOX5APFEN1USP7ENPP1EPHB4 | |
| SCHEMBL17645746 | 0.80 | BTK (0.41) | ENPP1BTKBDKRB1 | |
| SCHEMBL2781920 | 0.80 | NOS3 (0.47) | ALOX5APFEN1EPHB4NOS3NOS2 | |
| SCHEMBL17645694 | 0.77 | BTK (0.43) | ALOX5APFEN1BTKBDKRB1 | |
| SCHEMBL17670764 | 0.75 | MAPK1 (0.45) | ALOX5APFEN1BTKMTOR | |
| SCHEMBL17646014 | 0.75 | EPHX2 (0.58) | BTK | |
| SCHEMBL17645985 | 0.74 | GRM2 (0.37) | ALOX5APFEN1BTK | |
| SCHEMBL15471657 | 0.73 | ESR1 (0.46) | ALOX5APFEN1 | |
| SCHEMBL17555671 | 0.72 | CDK2 (0.43) | USP7NOS3NOS2 | |
| SCHEMBL19997549 | 0.72 | DYRK1A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ALOX5AP 3157/4885FEN1 3034/4885USP7 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.